MIR31HG

Across TCGA pan-cancer cohorts, MIR31HG Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIR31HG data layer compared with 25 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MIR31HG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR31HG expression acts as an unfavorable survival marker.

BLCA and HNSC are the cancer types where MIR31HG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	48	view →
HNSC	OS	Median	All	0.138	0.751	<.001	48	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MIR31HG–BLCA (OS)

Open the BLCA breakdown →